Regulation & policy

Supplements 101: Understanding European health claims

Supplements 101: Understanding European health claims

By Lauren Nicolle

The European dietary supplement regulatory system can seem complex and difficult to navigate. Here, NutraIngredients+ breaks down the answers to some of the most commonly asked regulatory questions with insights from leading experts in the field.

IPA opens China office, unveils upcoming plans

Vitafoods Asia 2025

IPA opens China office, unveils upcoming plans

By Tingmin Koe

The International Probiotics Association (IPA) has officially opened its China office located in Shanghai, and Executive Director George Paraskevakos recently spoke with NutraIngredients on the association’s plans in the country.

The ‘proteinification’ of everything

The ‘proteinification’ of everything

By Danielle Masterson

Once just a bottle shaker staple, protein is taking on new forms and finding its way into everything from soda to chips to macaroni and cheese.

FDA declares NMN lawful in dietary supplements

FDA declares NMN lawful in dietary supplements

By Stephen Daniells

The U.S. Food and Drug Administration (FDA) has responded to a Citizen Petition from the Natural Products Association (NPA) and the Alliance for Natural Health USA (ANH) on the status of NMN, declaring the vitamin B3 form to be lawful for use in dietary...

What do US tariffs against India mean for botanical exports?

What do US tariffs against India mean for botanical exports?

By Claudia Adrien

President Trump implemented 50% tariffs on goods from India 10 days ago in retaliation for India’s importation of Russian oil. According to the BBC, prolonged 50% tariffs could ‘shave off’ as much as 0.8% of India’s GDP.

South Korea bans imports of supplements containing 7-OH

South Korea bans imports of supplements containing 7-OH

By Tingmin Koe

South Korea’s Ministry of Food and Drug Safety (MFDS) has an import ban on dietary supplements, jellies, and beverages containing 7-hydroxymitragynine (7-OH) and has urged consumers to refrain from these products when doing cross-border e-commerce (CBEC)...

Short-staffed FDA delays NMN citizen petition response

Short-staffed FDA delays NMN citizen petition response

By Asia Sherman

The U.S. Food and Drug Administration (FDA) has delayed its response to a citizen petition regarding nicotinamide mononucleotide (NMN), citing agency-wide staffing reductions and administrative setbacks.